Modified tuberculosis vaccine as therapy against bladder cancer

March 5, 2020

The Max Planck Insitute for Infection Biology is sharing news of interest to the Immunology Community.

Therapy with VPM1002 is effective in bladder cancer patients

The human immune system can recognize and eliminate not only germs but also cancer cells. This is why treatments with weakened germs can help the immune system it ist fight against cancer.

The Max Planck Insitute for Infection Biology has developed a vaccine against TB which is currently in phase III trial. Less known is that this vaccine is also tested for treatment of bladder cancer and it has now shown a remarkable outcome in a clinical trial in preventing cancer recurrence.

clinical trial no.: NCT02371447 (https://clinicaltrials.gov/ct2/show/NCT02371447)

More News

ASI announces their new ASI Global Outreach Award

August 9, 2023

FIMSA Travel Awards for IUIS 2023 Congress

June 20, 2023ASI announces their new ASI Global Outreach Award, Federation of Immunological Societies of Asia-Oceania (FIMSA)

2023 World Laureates Association Prize (WLA Prize)

May 22, 2023

Michelson Prizes

April 12, 2023

2023 International Day of Immunology

February 23, 2023

IUIS celebrates the International Day of Women and Girls in Science on February 11

February 9, 2023

IUIS-FAIS-SANTHE-ISZ-Immuno-Zambia 2022

December 21, 2022ASI announces their new ASI Global Outreach Award, Education Committee (EDU)

Funding Opportunity from IUIS and FOCIS for Young Immunologists from the Developing World

December 1, 2022ASI announces their new ASI Global Outreach Award, Gender Equality Committee (GEC)

IUIS-GEC National Gender Equality Campaign – Competition4ideas

November 29, 2022ASI announces their new ASI Global Outreach Award, Gender Equality Committee (GEC)